scispace - formally typeset
A

Antonella Capozzi

Researcher at Sapienza University of Rome

Publications -  60
Citations -  1245

Antonella Capozzi is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Antiphospholipid syndrome & Lipid raft. The author has an hindex of 16, co-authored 51 publications receiving 959 citations.

Papers
More filters
Journal ArticleDOI

A New 4-phenyl-1,8-naphthyridine Derivative Affects Carcinoma Cell Proliferation by Impairing Cell Cycle Progression and Inducing Apoptosis

TL;DR: It is hypothesized that the dual effects of naphthyridine derivative on cell cycle and mitotic spindle were obtained at very low concentrations, i.e. micromolar concentrations, and could represent a new promising tool in the control of cancer cell proliferation.
Journal ArticleDOI

Oxidized Human Beta2-Glycoprotein I: Its Impact on Innate Immune Cells

TL;DR: The role of oxidative stress in β2-GPI-mediated immune response is described in the light of research experience and of relevant literature emerging in the field.
Journal ArticleDOI

LRP6 mediated signal transduction pathway triggered by tissue plasminogen activator acts through lipid rafts in neuroblastoma cells.

TL;DR: It is demonstrated that LRP6 mediated signal transduction pathway triggered by tPA acts through lipid rafts in neuroblastoma cells, suggesting that cyclodextrins, and potentially other drugs, such as statins, may represent an useful tool.
Journal ArticleDOI

"Non-criteria antiphospholipid antibodies": bridging the gap between seropositive and seronegative Antiphospholipid Syndrome.

TL;DR: In this article, the prevalence of noncriteria anti-phospholipid (aPL) antibodies and their role in the diagnosis, treatment and prognosis in a cohort of patients with clinical features consistent with a diagnosis of antiphospholine syndrome (APS), but persistently negative for criteria aPL-anti-cardiolipin antibodies (aCL), anti-β2-glycoprotein I antibodies (α-2-GPI), and lupus anticoagulant (LA) -named seronegative APS (SN-APS
Journal ArticleDOI

Acute longitudinal myelitis following Cryptococcus laurentii pneumonia in a patient with systemic lupus erythematosus

TL;DR: This is the first case of Cryptococcus laurentii infection and ALM in a patient with SLE who later developed a seronegative APS and the patient was treated with antimycotics, high doses of glucocorticoids and intravenous immunoglobulins with a significant clinical and radiological improvement.